Alkem Laboratories Limited has informed the Exchange about Attached please find update on incorporation of JV in Saudi
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Midcap 150 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alkem Laboratories has updated the stock exchanges about its Joint Venture in Saudi Arabia. The Board approved an amendment to the Shareholders' Agreement signed earlier in August 2025. Instead of Mr. Abdulaziz Alsheikh (the original JV partner) holding 49% personally, his wholly owned company, Vitals Biotech Company, will now hold the 49% stake. Alkem will continue to hold 51% in the JV, making it a subsidiary of the company. The change is essentially a restructuring of the partner side of the deal, with no change in ownership percentages or Alkem's control.
This is a procedural update rather than a material change—ownership ratios and Alkem's controlling 51% stake remain intact. Shareholders should note Alkem's continued international expansion into Saudi Arabia, which could open new revenue channels, but the immediate stock impact is likely neutral.